SLC22A18 Membrane Protein Introduction

Introduction of SLC22A18

Solute carrier family 22 member 18 (SLC22A18), which is a member of solute carrier family, is a protein encoded by the SLC22A18 gene in humans. This gene is within an important tumor suppressor gene region, which is one of several tumor suppressor-transferable fragments in the 11p15.5 gene domain. Mutations of this gene are involved in Wilms tumor, rhabdomyosarcoma, Beckwith-Wiedemann syndrome, adrenocortical carcinoma, and lung, ovarian, and breast cancer. This gene may play a role in malignant tumors and diseases involving the region, as well as transport chloroquine and quinine-related compounds in the kidney. Two alternative transcripts encoding the same contour have been described.

Basic Information of SLC22A18
Protein Name	Solute carrier family 22 member 18
Gene Name	SLC22A18
Aliases	Beckwith-Wiedemann syndrome chromosomal region 1 candidate gene A protein, Efflux transporter-like protein, Imprinted multi-membrane-spanning polyspecific transporter-related protein 1, Organic cation transporter-like protein 2 (ORCTL-2), Solute carrier family 22 member 1-like, Tumor-suppressing STF cDNA 5 protein, Tumor-suppressing subchromosomal transferable fragment candidate gene 5 protein, p45-Beckwith-Wiedemann region 1 A (p45-BWR1A)
Organism	Homo sapiens (Human)
UniProt ID	Q96BI1
Transmembrane Times	10
Length (aa)	424
Sequence	MQGARAPRDQGRSPGRMSALGRSSVILLTYVLAATELTCLFMQFSIVPYLSRKLGLDSIAFGYLQTTFGVLQLLGGPVFGRFADQRGARAALTLSFLAALALYLLLAAASSPALPGVYLLFASRLPGALMHTLPAAQMVITDLSAPEERPAALGRLGLCFGVGVILGSLLGGTLVSAYGIQCPAILAALATLLGAVLSFTCIPASTKGAKTDAQAPLPGGPRASVFDLKAIASLLRLPDVPRIFLVKVASNCPTGLFMVMFSIISMDFFQLEAAQAGYLMSFFGLLQMVTQGLVIGQLSSHFSEEVLLRASVLVFIVVGLAMAWMSSVFHFCLLVPGLVFSLCTLNVVTDSMLIKAVSTSDTGTMLGLCASVQPLLRTLGPTVGGLLYRSFGVPVFGHVQVAINTLVLLVLWRKPMPQRKDKVR

Function of SLC22A18 Protein

SLC22A18 is considered to be based on its chromosomal location at 11p15.5, mutations and abnormal splicing in several types of cancer, and downregulation of glioblastoma. Explosion homology analysis indicated that SLC22A18 is a member of the multispecific transporter and multidrug resistance gene family. Recently, SLC22A18 has been shown to be a tumor suppressor and a substrate for RING105. Structural mutations in SLC22A18 are rare, with individual point mutations reported in breast cancer cell lines, rhabdomyosarcoma cell lines, and Wilm's tumors and lung tumors. At the same time, the apparent deletion of hepatoblastoma and the loss of heterozygosity of hepatoma were also reported, suggesting that SLC22A18 may play a role in tumorigenesis.

Fig.1 The structure of SLC22A18 Protein.

Application of SLC22A18 Protein in Literature

Jung Y., et al. Characterization of SLC22A18 as a Tumor Suppressor and Novel Biomarker in Colorectal Cancer. Oncotarget. 2015, 6 (28): 25368–25380. PubMed ID: 26196590.

The authors propose that SLC22A18 is potentially a marker of diagnostic and prognostic values.
Chu S.H., et al. Promoter Methylation and Downregulation of SLC22A18 are Associated with the Development and Progression of Human Glioma. Journal of Translational Medicine. 2011, (9): 156. PubMed ID: 21359964.

This article reveals that SLC22A18 is an important tumor suppressor of gliomas, associated with decreased development and progression of gliomas by promoter methylation.
Chu S.H., et al. Predictive Value of the SLC22A18 Protein Expression in Glioblastoma Patients Receiving Temozolomide Therapy. Journal of Translational Medicine. 2013, (11): 69. PubMed ID: 23514245.

These results indicate that the lack of SLC22A18 protein expression is a better predictive tumor biomarker in patients with GBM who are treated with temozolomide, compared with promoter methylation.
Chu S.H., et al. Elevated Expression of Solute Carrier Family 22 Member 18 Increases the Sensitivity of U251 Glioma Cells to BCNU. Oncology Letters. 2011, 2 (6): 1139–1142. PubMed ID: 22848278.

These results indicate that SLC22A18 has a function of promoting apoptosis in glioma cells.
Bhutia Y.D., et al. SLC Transporters as a Novel Class of Tumour Suppressors: Identity, Function and Molecular Mechanisms. The Biochemical journal. 2016, 473 (9): 1113–1124. PubMed ID: 27118869.

The results show that SLC22A18 may be an organic cation transporter, but the identity of its physiological substrates is undefined.

SLC22A18 Preparation Options

To obtain the soluble and functional target protein, the versatile Magic™ membrane protein production platform in Creative Biolabs enables many flexible options, from which you can always find a better match for your particular project. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SLC22A18 antibody development services.

Creative Biolabs' skillful scientists are glad to leverage our expertise and advanced technologies to help you with the member protein research. If you are interested, please feel free to contact us for more details.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: